For the love of god and all that is holy!!!

Given that (a) the FDA is toothless at best and (b) doctors exhibit a mindless uncritical groupthink that rivals the Heaven's Gate cult, I am beginning to wonder if the Securities and Exchange Commission (SEC) might be the best route to stop some of this idiocy.

This "analysis" is technically from an independent consortium and therefore the disclosure requirements would not necessarily apply, but if I were a Lilly shareholder I would have to be a bit perturbed by the disconnect between the "science" and the "market science."

I'd probably need some Cymbalta for my depression-pain . . . [sigh] . . .

The only time I have ever heard the word "gold standard" was in regard to Lithium and Clozaril.

I've spoken to quite a few psychiatrists (in the last year inpatient house docs in psych wards as well as long-term residential care facilities) on behalf of a family member.As a matter of fact, the long-term residential facility psych doc told me (July 2006)that 60% of his patients are on Clozaril(and free of a state hospital as a result.)

Not one psychiatrist referred to Zyprexa as a "gold standard". As a matter of fact (Lilly readers)Zyprexa was replaced with Clozaril and Lithium.

I have a nearly 8 year home-study (my kid)that is proof Zyprexa is no wonder-drug or gold standard.

An observation I made:

DR when comparing atypicals for schizophrenia, left Seroquel out and hailed Zyprexa as the "gold standard" for the illness. On the flip side, when DR compared atypicals for bipolar disorder, they left Zyprexa out and hailed Seroquel as the second coming to surpass Lamictal.

Hmm... Those thought-leading psychiatrists must have been swayed by a generic drug name dinerovox.

Actually, "gold-standard" was another term that was revealed in patent literature regarding insulin. As scientists sought to "prove" the value and need of rDNA genetically-engineered insulin, the patent literature stated that "Beef Ultralente Insulin" was the gold-standard for basal insulins"--the only insulin that provided 24-36 hour basal coverage without a peak.

Need I tell you which--of all the natural insulins Lilly has removed from the market--was the first to be pulled from the American marketplace? Beef Ultralente. For more than a decade, now, Type 1 diabetics have had the "choice" of using pump technology (both expensive and problematic) or try to cover basal insulin needs with peaky insulins.

As I've mentioned before in Philip's columns, Lilly's marketing technology was defined and refined using their rDNA insulin promotion! Zyprexa is only their latest and greatest "success."